At the news
? NEUTRALIMPACT 3/10 SC 13G/A filed Nov 5, 2026 at 13:10 ET
FMR LLC (Fidelity) filed an amended Schedule 13G disclosing a 9.5% passive stake in Alnylam Pharmaceuticals as of September 30, 2026, up from a prior filing. This is a routine update for a large passive holder and does not signal any change in investment intent or control.
- FMR LLC reported beneficial ownership of 12,675,052.96 shares of Alnylam common stock as of September 30, 2026.
- The stake represents 9.5% of the outstanding shares.
- The filing is an amendment to Schedule 13G, certifying passive intent under Rule 13d-1(b).
- Fidelity Management & Research Company LLC is the entity within the FMR group that beneficially owns 5% or more of the class.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access